Conversely, the National Cancer Institute cautions that dietary supplements like vitamin D can alter cancer treatment efficacy and safety, as evidenced by Christakos et al., who describe high-dose vitamin D inducing CYP3A4 via VDR/PXR pathways, potentially accelerating the metabolism of drugs like imatinib and increasing toxicity risk [55]. This evidence concerns the gene CYP3A4 and cancer.